Orca Bio Secures FDA RMAT Status for Orca-Q Therapy
MENLO PARK, Calif., April 28, 2026 Orca Bio has announced that the U.S. Food and Drug Administration (FDA) has...
AI drug discovery Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
MENLO PARK, Calif., April 28, 2026 Orca Bio has announced that the U.S. Food and Drug Administration (FDA) has...
MENLO PARK, California | January 9, 2026 — Orca Bio, a late-stage biotechnology company focused on high-precision allogeneic cell...
